Lightbits Labs Named Storage Company of the Year and Receives Storage Hardware Award for SuperSSD NVMe/TCP at SDC Awards
3.12.2019 16:00:00 EET | Business Wire | Press release
At the recent SDC Awards gala here, Lightbits Labs took home two prestigious awards, Storage Company of the Year and Hardware Innovation of the Year. Lightbits received the nod for storage company of the year for its software defined storage (SDS) solution that brings hyperscale efficiency to on-premise cloud infrastructure with low-latency composable storage. Lightbits’ SuperSSD NVMe/TCP Storage Server , the World’s First Ultra-High Capacity, High Performance SSD Storage Appliance solution was selected as the most innovative hardware solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191203005290/en/
Lightbits Labs takes home storage company of the year and wins storage hardware award for SuperSSD NVMe/TCP at the SDC Awards. Posing with the awards from left to right are: Kam Eshghi, Chief Strategy Officer, Shirley Kirzner, Eran Kirzner, Chief Executive Officer and Co-Founder, George Agasandian, Director of Solutions Engineering and Co-Founder, Ofir Efrati, VP of Engineering and Co-Founder, Shaul Galia, Chief Operations Officer, and Miki Avni, Chief Financial Officer. (Photo; Business Wire)
The SDC (Storage, Digitalization + Cloud) Awards, now in their 10th year, recognize and reward success in the products and services that are foundational to digital transformation. Lightbits received the honor for how the company is reimagining hyperscale storage for next-generation applications.
Co-founded by veteran Israeli entrepreneur and founder of Annapurna Avigdor Willenz, Lightbits introduced three groundbreaking technologies in its first year out of stealth mode: LightOS, LightField, and SuperSSD. The company was cited for its leadership in delivering software defined solution that runs on commodity hardware to disaggregate storage and compute over standard networks, allowing them to scale independently (increasing flexibility & efficiency) and maximizing resource utilization (lowering TCO) while delivering performance that is similar to direct-attached SSDs. Lightbits pioneered NVMe/TCP so its solution is easy to deploy at scale.
“Being recognized by our peers and voters from around the globe for this award highlights the increasingly important role of practical, smart and forward-thinking storage solutions for true digital transformation,” said Eran Kirzner, co-founder and CEO at Lightbits Labs. “Companies are responsible for vast amounts of data through both public and private clouds, and the volume of data continues to grow exponentially. We’re proud that our solutions are being recognized for their transformational role in addressing the data storage challenges that are so prevalent in enterprises today.”
In March 2019, Lightbits introduced its groundbreaking LightOS and LightField. The LightOS software and LightField storage acceleration card provide a high-performance, end-to-end disaggregation solution that can scale without requiring any changes to data center clients or network infrastructure. They were the industry’s first NVMe/TCP solutions to provide a Global Flash Translation Layer (GFTL) running over high-performance standard networks. The solutions allow private clouds and software-as-a-service (SaaS) providers to capitalize on the application performance of using local NVMe SSDs with the simplicity and efficiency of hyperscale solutions.
As trailblazers of a new storage paradigm, Lightbits’ solutions are successfully being used in industry-leading cloud data centers around the globe. The company is gaining industry recognition for its ground-breaking solutions and has received three industry awards over the past six months.
Lightbits Labs Resources
For additional information, contact info@lightibtslabs.com
About Lightbits Labs™
Lightbits Labs, founded in 2016, is remaking modern cloud infrastructure on a global scale. The company’s mission is to reinvent the way storage and networking are conducted in data centers. As trailblazers in this field, its solutions are successfully being used in industry-leading private cloud and enterprise data centers around the globe. With strategic investors including Dell Technology Capital and Micron, and with investments from Chairman and co-founder Avigdor Willenz, Lip-Bu Tan (CEO of Cadence and chairman of Walden International) and Marius Nacht, (Co-Founder and Chairman of Check Point Software), Lightbits Labs is disaggregating storage and compute to improve performance and TCO. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005290/en/
Contact information
Alan Ryan/Marianne Dempsey
alanryan@rainierco.com/ mdempsey@rainierco.com
508-475-0025, ext. 116 or 115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom